z-logo
Premium
Oryeongsan improves diabetes‐associated renal proliferation and fibrosis in cultured rat mesangial cells
Author(s) -
Yoon Jung Joo,
Lee Yun Jung,
Lee So Min,
Lee Yong Pyo,
Kim Dae Hwan,
Lee Bin,
Kang Dae Gill,
Lee Ho Sub
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.702.8
Subject(s) - ctgf , medicine , diabetic nephropathy , endocrinology , fibrosis , glomerulosclerosis , diabetes mellitus , cancer research , kidney , growth factor , proteinuria , receptor
Diabetic nephropathy (DN) associated with morbidity and mortality of diabetic patients. Mesangial cell proliferation is known as the major pathologic features such as glomerulosclerosis and renal fibrosis. Oryeongsan (ORS), traditional herbal formula, is widely used for the treatment of nephrosis, dropsy, and uremia. Thymidine incorporation under HG was significantly accelerated, which was inhibited by ORS in a dose dependent manner. Pretreatment of ORS induced down‐regulation of cyclins/CDKs and up‐regulation of CDK inhibitor, p21waf1/cip1 and p27kip1 expression. In addition, ORS reduced HG‐induced RMCs proliferation by suppression of the MAPK phospholyration such as ERK, JNK, and p38. ORS significantly suppressed the HG‐induced ROS production. HG enhanced expression of □brosis biomarkers such as collagen IV and CTGF, which was markedly attenuated by ORS. Moreover, ORS inhibits HG‐induced fibronectin mRNA expression. ORS decreased TGF‐â1 and p‐Smad2/Smad4 expression, whereas increased Smad7 expression under HG. Thus, ORS promoted ECM degradation through disturbing TGF‐â– SMAD signaling. Taken together, these results demonstrate that ORS has a protective effect on renal proliferation and fibrosis. These results suggest that ORS might prove to be effective in the treatment of renal dysfunction leading to DN.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here